Two squirts of a nasal spray, spaced days apart, were enough to quiet overactive immune cells in the brains of aging mice and sharpen their performance on memory tests. That is the central finding of a peer-reviewed study published in April 2026 in the Journal of Extracellular Vesicles by researchers at Texas A&M University, led by senior author Ashok K. Shetty, a professor in the Department of Molecular and Cellular Medicine and associate director of the Institute for Regenerative Medicine.
The spray did not contain a conventional drug. Instead, it delivered extracellular vesicles, or EVs, nanoscale packets naturally released by cells that carry proteins, RNA, and other signaling molecules capable of reprogramming the behavior of recipient cells. These particular EVs were harvested from human neural stem cells grown in the lab from induced pluripotent stem cells, a cell type selected because it closely mirrors the biology of the developing brain.
The treatment targeted the hippocampus, the brain region most critical for forming and retrieving memories, and it worked by dialing down two well-known inflammatory signaling cascades that ramp up with age. With new dementia diagnoses in the United States on track to approach one million per year by 2060, according to projections from the Alzheimer’s Association, even early-stage animal data on non-invasive brain therapies draws serious attention from the research community and the millions of families already living with cognitive decline.
What the study found
Shetty’s team administered two intranasal doses of the engineered EVs to mice in late middle age, roughly equivalent to humans in their late 50s or early 60s. After treatment, the researchers examined hippocampal tissue and found reduced activity in two molecular circuits: the NLRP3 inflammasome pathway and the cGAS-STING pathway. Both are established drivers of chronic neuroinflammation, the persistent, low-grade immune activation that accelerates brain aging and has been linked to Alzheimer’s disease and other forms of dementia.
By dampening those signals, the EV therapy appeared to shift microglia, the brain’s resident immune cells, toward a calmer, less reactive state. The study also reported improvements in mitochondrial-related readouts, suggesting the treatment may help restore energy metabolism in aging brain tissue. On behavioral tests designed to measure spatial learning and memory, the treated mice outperformed untreated aged controls, though the paper did not report exact percentage gains.
Why the delivery route matters
One of the biggest obstacles in treating brain diseases is the blood-brain barrier, a tightly sealed membrane that blocks most drugs from reaching neural tissue. The nasal passage offers a workaround. A separate biodistribution study from the same Texas A&M group, published in Frontiers in Neuroscience, confirmed that these EVs, when delivered through the nose, can be detected across multiple forebrain regions and incorporate directly into neurons and microglia in a well-established Alzheimer’s mouse model known as 5xFAD.
A related paper in the same journal added mechanistic depth, showing that intranasal EVs alter the gene-expression profile of activated microglia and reduce inflammasome-related features, with effects that persisted in the hippocampus even after treatment ended. Together, these studies demonstrate that the delivery method works and that the vesicles reach their intended cellular targets.
The Texas A&M group has also tested intranasal EV delivery in traumatic brain injury models. Studies indexed in Brain, Behavior, and Immunity and Frontiers in Molecular Neuroscience found that intranasal EVs suppressed NLRP3 and related inflammatory signaling after injury, eased neurogenesis decline, reduced synapse loss, and restored key growth-factor pathways. Those results address a different condition, but they reinforce the biological plausibility that EVs delivered through the nose can engage immune and neuronal cells in the brain and produce consistent anti-inflammatory effects.
What the study cannot tell us yet
Every result in this research line comes from mouse models, and the distance between promising animal data and an effective human therapy remains vast. The aging study’s behavioral tests confirm a directional improvement in memory, but without precise effect sizes, it is hard to gauge how meaningful the cognitive benefit would be in practice.
Durability is another open question. The longest follow-up periods in these experiments extend only weeks beyond treatment. Whether two doses can produce lasting protection over months or years has not been tested. The studies also used small cohorts of laboratory mice housed under tightly controlled conditions, a setting that does not reflect the genetic diversity, environmental exposures, or overlapping health problems that define human aging.
On the mechanistic side, the precise cargo molecules inside the EVs that drive the anti-inflammatory effects have not been fully identified. Researchers also do not yet know whether the treatment would interact with medications commonly used by older adults, or whether repeated dosing could eventually trigger immune responses against the human-derived vesicles in a different species. The traumatic brain injury studies used EVs from mesenchymal stem cells rather than neural stem cells, so the degree to which findings transfer across cell sources remains an open question.
Timing and dosing need further exploration as well. The aging mice received treatment in late middle age, but it is unclear whether earlier intervention, more frequent dosing, or booster treatments later in life would strengthen or extend the effects. Whether the same schedule would be safe in much older brains already showing substantial neurodegeneration is unknown.
How this fits into the broader landscape
Intranasal delivery to the brain is not a new idea. Intranasal insulin, for example, has been tested in Phase II and Phase III clinical trials for mild cognitive impairment and Alzheimer’s disease, with mixed but instructive results. What distinguishes the Texas A&M approach is the use of stem cell-derived vesicles rather than a single molecule, potentially allowing a broader range of biological signals to reach the brain in a single dose.
Translating that concept into a clinical product would require clearing significant manufacturing and regulatory hurdles. Producing EVs from human stem cells at scale, under the strict quality controls required for human use, is technically complex and expensive. Regulators would need clear data on batch-to-batch consistency, potential contaminants, and long-term safety before greenlighting large-scale trials in older adults who often take multiple medications and manage other chronic conditions.
No human safety or efficacy trials of this specific EV formulation have been reported. For now, the research is best understood as a proof of concept: engineered vesicles from human stem cells can be delivered non-invasively to the aging mouse brain, can calm overactive immune pathways in the hippocampus, and can nudge aging neural circuits toward better function under controlled laboratory conditions. The next steps, including identifying the active cargo, testing durability over longer time frames, and designing first-in-human safety studies, will determine whether this line of work can eventually move from the lab bench toward the clinic.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
